AI-based Clinical Trials Solution Providers Market Segmentation:
Application Segment Analysis
The oncology segment is anticipated to garner the largest market share over the forecast period, owing to the increasing prevalence of cancer worldwide and the increasing number of drug trials. In 2019, oncology accounted for the most popular therapy area for non-industry-sponsored clinical trials, estimated for 26% of all clinical trials. In the recent times, there has been rise in drug based clinical trials in oncological research, this in turn have raised the demand for AI-based equipment in the clinical research. Moreover, growing number of market players opting for oncology-based simulated instruments for clinical preliminaries is driving the growth.
Clinical Trial Phase Segment Analysis
The Phase II segment is expected to account for the fastest market share in the forecast period. Phase II held a market share of 46.1% in 2022, owing to the prevalence of a large number of clinical trials. The growing incorporation of AI tools for immediate results from the desired outcome of drug trials and also the collection of data at the same timeis driving growth of the segment. Additionally, Phase I segment is anticipated to show the fastest growth rate in the forecast period. As phase I is advantageous for patient retention, better trial design and patient recruitment, the ai-based solution is expected to grow in the forecast period.
Our in-depth analysis of the global market includes the following segments:
|
By Application |
|
|
By Clinical Trial Phase |
|
|
By End User |
|
